Examkin

Question

Difficulty: HardGynecologic Oncology

A 58-year-old woman presents to the clinic with a 3-week history of continuous, thin, watery vaginal discharge that occasionally leaves pink stains on her undergarments. She reached menopause at age 51. Her medical history is notable for estrogen receptor-positive breast cancer diagnosed 4 years ago, which was treated with a lumpectomy and radiation therapy. She has been taking anastrozole for the past 3 years. Since starting the medication, she reports significant vaginal dryness and dyspareunia. Her vital signs are within normal limits. Speculum examination reveals pale, thin, and dry vaginal mucosa with a loss of rugation. There are no lacerations in the vaginal vault, but a small amount of dark red fluid is noted pooling at the external cervical os. Bimanual examination demonstrates a small, mobile, non-tender uterus without adnexal masses. Which of the following is the most appropriate next step in the management of this patient?

  1. Endometrial biopsyAnswer
  2. B
    Prescription of low-dose vaginal estrogen cream
  3. C
    Transabdominal pelvic ultrasonography
  4. D
    Colposcopy with endocervical curettage
  5. E
    Papanicolaou test and human papillomavirus cotesting

Answer

Endometrial biopsy
Any vaginal bleeding in a postmenopausal woman must be evaluated to rule out endometrial carcinoma. This holds true even if the bleeding is merely described as a pink-tinged discharge or if blood is incidentally found at the cervical os. The standard initial diagnostic step is either an endometrial biopsy or a transvaginal ultrasound (which must show an endometrial stripe ≤ 4 mm to safely exclude malignancy). In this patient, the use of anastrozole has led to profound estrogen deficiency, causing the visible signs of genitourinary syndrome of menopause (atrophic vaginitis). While atrophic vaginitis is the most common cause of postmenopausal bleeding, a clinician cannot safely attribute the bleeding to this benign condition without first strictly excluding malignancy. Because transvaginal ultrasound is not an option here, an endometrial biopsy is explicitly indicated as the next best step.

Step-by-Step Solution

1
Identify the primary clinical presentation.
The patient has a pink-tinged vaginal discharge and dark red fluid pooling at the cervical os, which functionally constitutes postmenopausal bleeding (PMB).
Any spotting, bleeding, or blood-tinged discharge in a postmenopausal woman is abnormal and requires formal oncologic evaluation.
2
Analyze the impact of the patient's medical history.
The use of anastrozole (an aromatase inhibitor) causes profound estrogen depletion, resulting in her severe genitourinary syndrome of menopause (atrophic vaginitis).
Recognizing the cause of her vaginal dryness explains a potential benign source of bleeding, acting as a cognitive distractor.
3
Apply the standard diagnostic algorithm for postmenopausal bleeding.
Despite having a highly plausible benign etiology for the bleeding (vaginal atrophy), clinical guidelines mandate ruling out endometrial carcinoma using either an endometrial biopsy or a transvaginal ultrasound.
Endometrial cancer must be formally excluded before attributing PMB to atrophy.
4
Select the correct intervention from the given options.
Because transvaginal ultrasound is not listed as an option (only the inadequate transabdominal route is present), direct tissue sampling via an endometrial biopsy is the definitive next step.
Endometrial biopsy directly assesses for the presence of hyperplasia or carcinoma.

Key Concept

All instances of postmenopausal bleeding must be evaluated with either an endometrial biopsy or a transvaginal ultrasound to rule out endometrial carcinoma, even when an obvious benign etiology like atrophic vaginitis is present.

Alternative Method

If transvaginal ultrasound (TVUS) had been an available option, it would also be considered a correct first step. An endometrial stripe thickness of ≤ 4 mm on TVUS has a highly negative predictive value for endometrial cancer, which would allow the clinician to safely proceed with treating the vaginal atrophy.
Estimated Time:1m 15s
Rate this question

Topics

Gynecologic Oncology

More questions from this topic